Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.47 |
| ▸ | CDK4 | P11802 | 5/20 | 0.47 |
| ▸ | CCND1 | P24385 | 5/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.47 |
| ▸ | CDK2 | P24941 | 5/20 | 0.47 |
| ▸ | CAMK2B | Q13554 | 4/20 | 0.47 |
| ▸ | CAMK2G | Q13555 | 4/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29755092 | 0.85 | CDK4 (0.51) | IMPDH2IMPDH1CHEK1CCNE2CDK4 | |
| SCHEMBL28770596 | 0.85 | CDK4 (0.51) | IMPDH2IMPDH1CHEK1CCNE2CDK4 | |
| SCHEMBL3876965 | 0.79 | IMPDH2 (0.55) | IMPDH2IMPDH1CHEK1CCNE2CDK4 | |
| SCHEMBL22787315 | 0.79 | CDK4 (0.47) | CHEK1CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL14198729 | 0.79 | MEN1 (0.73) | IMPDH2IMPDH1CHEK1CCNE2CDK4 | |
| SCHEMBL23926188 | 0.79 | CDK4 (0.50) | CHEK1CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL5830117 | 0.79 | CHEK1 (0.56) | IMPDH2IMPDH1CHEK1CCNE2CDK4 | |
| SCHEMBL17094777 | 0.76 | AR (0.58) | IMPDH2IMPDH1MEN1MAPTKMT2A | |
| SCHEMBL3889086 | 0.76 | IMPDH2 (0.51) | IMPDH2IMPDH1CHEK1CCNE2CDK4 | |
| SCHEMBL22079859 | 0.75 | MAPT (0.59) | CHEK1CCNE2CDK4CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115298185-B | Heterocyclic compound and organic light-emitting element comprising same | 株式会社LG化学 | 2024-06-18 | — | — | CN | disclosed |
| US-20230146653-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230146653-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| CN-115298185-A | Heterocyclic compound and organic light-emitting element comprising same | 株式会社LG化学 | 2022-11-04 | — | — | CN | disclosed |
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2006060122-A9 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS INC (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006060127-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060122-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005016885-A2 | COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE | ARTESIAN THERAPEUTICS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ADRB3, PDE3A, PDE3B | IMPDH2 1535/4885IMPDH1 1577/4885CHEK1 3497/4885 |
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ADRB3, PDE3A, ADRB1 | IMPDH2 1730/4885IMPDH1 1334/4885CHEK1 3036/4885 |
| US-20230146653-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, AOX1 | IMPDH2 1753/4885IMPDH1 1648/4885CHEK1 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.